

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 September 2023 (28.09.2023)



(10) International Publication Number
WO 2023/180898 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 31/53 (2006.01)
C07D 401/14 (2006.01) C07C 55/10 (2006.01)

(21) International Application Number:

PCT/IB2023/052709

(22) International Filing Date:

20 March 2023 (20.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/323,005 23 March 2022 (23.03.2022) US

(71) Applicant: **ARRAY BIOPHARMA INC.** [US/US]; 3200 Walnut Street, Boulder, Colorado 80301 (US).

(72) Inventors: **BROWN, Katie Keaton**; 7221 Spring Creek Cir., Niwot, Colorado 80503 (US). **COWDREY, Connor James**; c/o Array Biopharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US). **GOODWIN, Aaron Keith**; c/o Array Biopharma Inc., 3200 Walnut Street, Boulder, Colorado 80301 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: CRYSTALLINE SALT FORM OF A SHP2 INHIBITOR




FIG. 1

(57) Abstract: This invention relates to a crystalline anhydrous form of (S)-1'-6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine mono succinate salt Form I. The invention also relates to pharmaceutical compositions comprising this crystalline form, and to methods of using the crystalline form and such compositions for the treatment of abnormal cell growth, such as cancer, in a mammal.

WO 2023/180898 A1